“We thank Joe for his contributions and commitment to AngioDynamics over the years, including his leadership in guiding the company through various regulatory challenges, implementing growth drivers into all 3 business franchises and integrating the Navilyst acquisition. We wish him the very best in his future endeavours,” chairman Howard Donnelly said in prepared remarks.
“Having recently managed operations and driven growth for a $1.8 billion global business, Jim Clemmer is uniquely positioned to lead AngioDynamics as we accelerate our growth and bring innovative products to the patients who need them,” Donnelly said. “We are confident Jim’s leadership and expertise will help AngioDynamics improve margins, drive international growth and ultimately maximize shareholder value.” Read More
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.